X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3997) 3997
Newsletter (19) 19
Book Chapter (7) 7
Newspaper Article (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3691) 3691
erlotinib hydrochloride (2711) 2711
oncology (2122) 2122
erlotinib (2022) 2022
lung neoplasms - drug therapy (1956) 1956
female (1868) 1868
carcinoma, non-small-cell lung - drug therapy (1670) 1670
male (1643) 1643
quinazolines - therapeutic use (1454) 1454
middle aged (1414) 1414
aged (1308) 1308
gefitinib (1277) 1277
receptor, epidermal growth factor - antagonists & inhibitors (1277) 1277
protein kinase inhibitors - therapeutic use (1091) 1091
chemotherapy (985) 985
antineoplastic agents - therapeutic use (970) 970
lung neoplasms - pathology (936) 936
adult (914) 914
cancer (908) 908
mutation (895) 895
receptor, epidermal growth factor - genetics (851) 851
quinazolines - administration & dosage (846) 846
lung neoplasms - genetics (821) 821
treatment outcome (796) 796
quinazolines - pharmacology (746) 746
antineoplastic combined chemotherapy protocols - therapeutic use (740) 740
carcinoma, non-small-cell lung - pathology (715) 715
cell line, tumor (698) 698
animals (675) 675
lung cancer (675) 675
quinazolines - adverse effects (660) 660
carcinoma, non-small-cell lung - genetics (658) 658
growth-factor receptor (647) 647
lung cancer, non-small cell (637) 637
epidermal growth factor (634) 634
egfr (628) 628
aged, 80 and over (609) 609
protein kinase inhibitors - pharmacology (566) 566
care and treatment (548) 548
cell lung-cancer (547) 547
receptor, epidermal growth factor - metabolism (512) 512
mice (468) 468
antineoplastic agents - pharmacology (467) 467
adenocarcinoma - drug therapy (464) 464
disease-free survival (464) 464
tyrosine kinase inhibitor (456) 456
respiratory system (451) 451
erlotinib hydrochloride - therapeutic use (437) 437
non-small cell lung cancer (412) 412
respiratory tract diseases (406) 406
therapy (406) 406
neoplasm staging (400) 400
protein kinase inhibitors - adverse effects (393) 393
expression (382) 382
pharmacology & pharmacy (378) 378
mutations (372) 372
tyrosine (372) 372
lung neoplasms - mortality (366) 366
epidermal growth factor receptor (360) 360
open-label (357) 357
survival (357) 357
hematology, oncology and palliative medicine (354) 354
analysis (352) 352
research (349) 349
prognosis (347) 347
erlotinib hydrochloride - administration & dosage (340) 340
carcinoma, non-small-cell lung - mortality (338) 338
antibodies, monoclonal, humanized (333) 333
cetuximab (333) 333
protein kinase inhibitors - administration & dosage (333) 333
tyrosine kinase inhibitors (332) 332
acquired-resistance (330) 330
antineoplastic agents - adverse effects (325) 325
adenocarcinoma (322) 322
erlotinib hydrochloride - pharmacology (319) 319
tumors (315) 315
bevacizumab (306) 306
lung neoplasms - metabolism (304) 304
deoxycytidine - analogs & derivatives (296) 296
erbb receptors - antagonists & inhibitors (290) 290
1st-line treatment (279) 279
phase-iii trial (278) 278
combination (276) 276
trial (276) 276
erbb receptors - genetics (275) 275
gemcitabine (275) 275
cell proliferation - drug effects (271) 271
drug resistance, neoplasm (268) 268
drug therapy (266) 266
retrospective studies (264) 264
survival rate (264) 264
nsclc (262) 262
antineoplastic agents - administration & dosage (261) 261
pancreatic neoplasms - drug therapy (255) 255
metastasis (251) 251
medicine & public health (249) 249
kinases (241) 241
resistance (241) 241
antineoplastic combined chemotherapy protocols - adverse effects (238) 238
neoplasms (236) 236
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3847) 3847
French (64) 64
Chinese (50) 50
Japanese (50) 50
German (34) 34
Spanish (12) 12
Hungarian (9) 9
Czech (7) 7
Danish (4) 4
Dutch (4) 4
Portuguese (4) 4
Polish (3) 3
Korean (2) 2
Norwegian (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2010, Volume 73, Issue 2, pp. 195 - 202
Abstract Purpose The goal of this study was to assess the safety and tolerability of icotinib hydrochloride (BPI-2009H... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Icotinib hydrochloride | Adverse events | Erlotinib | Tyrosine kinase inhibitor | Anti-tumor activity | Non-small-cell lung cancer | Pharmacokinetics | Gefitinib | Epidermal growth factor receptor | SURVIVAL | ESOPHAGEAL | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | EXON-21 MUTATIONS | IMPACT | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | PROTEIN EXPRESSION | GENE COPY NUMBER | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Administration, Oral | Proto-Oncogene Proteins p21(ras) - genetics | Crown Ethers - blood | Humans | Middle Aged | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Folliculitis - chemically induced | Quinazolines - blood | Crown Ethers - therapeutic use | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Antineoplastic Agents - blood | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Crown Ethers - adverse effects | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Medical colleges | Medical research | Care and treatment | Lung cancer, Non-small cell | Complications and side effects | Chemotherapy | Epidermal growth factor | Electrocardiogram | Phenols | Electrocardiography | Medicine, Experimental | Respiratory tract diseases | Cancer | Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 2016, Volume 229, pp. 80 - 92
Pretreatment of lung cancer cells with epidermal growth factor receptor (EGFR) inhibitor erlotinib has been recently reported that could dramatically synergize... 
pH-sensitive | Charge conversion | MSN | Erlotinib | DOX | Synergistic therapy | CLATHRIN-MEDIATED ENDOCYTOSIS | CELLS | DRUG-DELIVERY | CHITOSAN | TUMOR | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | PACLITAXEL | NANOPARTICLES | ENHANCED PERMEABILITY | CANCER-TREATMENT | PHARMACOLOGY & PHARMACY | Doxorubicin - therapeutic use | Drug Carriers - therapeutic use | Nanoparticles - chemistry | Apoptosis - drug effects | Benzoates - chemistry | Humans | Erlotinib Hydrochloride - chemistry | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Protein Kinase Inhibitors - chemistry | Nanoparticles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Drug Therapy, Combination | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | A549 Cells | Cell Survival - drug effects | Erlotinib Hydrochloride - pharmacokinetics | Mice, Inbred C57BL | Erlotinib Hydrochloride - administration & dosage | Phosphatidylcholines - chemistry | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Doxorubicin - pharmacokinetics | Carcinoma, Lewis Lung - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Drug Liberation | Drug Carriers - pharmacokinetics | Erlotinib Hydrochloride - therapeutic use | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Membrane lipids | Anthracyclines | Epidermal growth factor | Hydrogen-ion concentration | Lung cancer | Surface active agents | Drug discovery | Index Medicus
Journal Article
by Wu, Y.-L and Zhou, C and Liam, C.-K and Wu, G and Liu, X and Zhong, Z and Lu, S and Cheng, Y and Han, B and Chen, L and Huang, C and Qin, S and Zhu, Y and Pan, H and Liang, H and Li, E and Jiang, G and How, S.H and Fernando, M.C.L and Zhang, Y and Xia, F and Zuo, Y
Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 9, pp. 1883 - 1889
Journal Article
Angewandte Chemie (International ed.), ISSN 1433-7851, 2018, Volume 57, Issue 46, pp. 15040 - 15044
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 55, pp. 131 - 139
Abstract Aim The aim of this study was to investigate if biomarkers of individual drug metabolism, respectively, the erlotinib/O-desmethyl-erlotinib metabolic... 
Hematology, Oncology and Palliative Medicine | Erlotinib/O-desmethyl-erlotinib ratio | EGFR inhibitor-induced skin rash | Erlotinib metabolic ratio | Predictive biomarker | PLUS GEMCITABINE | MANAGEMENT | PANCREATIC-CANCER | PHASE-III | TOXICITY | CELL LUNG-CANCER | THERAPY | PHARMACOKINETICS | ONCOLOGY | RECEPTOR TYROSINE KINASE | ADVERSE EVENTS | Exanthema - diagnosis | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Protein Kinase Inhibitors - adverse effects | Exanthema - chemically induced | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Erlotinib Hydrochloride - pharmacokinetics | Adenocarcinoma - blood | Pancreatic Neoplasms - pathology | Adenocarcinoma - drug therapy | Disease Progression | Protein Kinase Inhibitors - blood | Erlotinib Hydrochloride - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - enzymology | Germany | Lung Neoplasms - pathology | Pancreatic Neoplasms - drug therapy | Drug Dosage Calculations | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Biotransformation | Adult | Female | Pancreatic Neoplasms - mortality | Carcinoma, Non-Small-Cell Lung - pathology | Severity of Illness Index | Pancreatic Neoplasms - blood | Dealkylation | Adenocarcinoma - enzymology | Erlotinib Hydrochloride - administration & dosage | Kaplan-Meier Estimate | Pancreatic Neoplasms - enzymology | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - blood | Aged | Lung Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Epidermal growth factor | Erlotinib | Skin care products | Physiological aspects | Rash (Dermatology) | Skin | Biological markers
Journal Article
Daru, ISSN 1560-8115, 2010, Volume 18, Issue 3, pp. 179 - 184
.... In the present study, the mutual interaction of anticancer drug erlotinib hydrochloride with bovine serum albumin (BSA... 
Albumin | Erlotinib hydrochloride | Fluorescence quenching | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | FLAVONOIDS | BINDING | Original
Journal Article
Journal of controlled release, ISSN 0168-3659, 2017, Volume 246, pp. 120 - 132
Journal Article